Processing
Processing. Please wait...

Biogen insider: Gregory Covino Biogen insider:  Gregory Covino

   All Insiders    
   

Chief Accounting Officer, Vice President - Finance

Mr. Gregory F. Covino is Chief Accounting Officer Vice President Finance of Biogen Idec Inc. since April 2012. Prior to that Mr. Covino served at Boston Scientific Corporationrationration a medical device company as Vice President Corporationrationrate Analysis and Control since March 2010 having responsibility for the company internal audit function and as Vice President Finance International from February 2008 to March 2010 having responsibility for the financial activities of the company international division. Prior to that Mr. Covino held several finance positions at Hubbell Incorporated an electrical products company including Vice President Chief Accounting Officer and Controller from 2002 to January 2008 Interim Chief Financial Officer from 2004 to 2005 and Director Corporationrationrate Accounting from 1999 to 2002
Age: 48  President Since 2012      
617-679-2000  http://www.biogenidec.com
Gregory Covino Education
Covino received his B.S. in Business Administration from Bryant University.

Management Efficency

The company has return on total asset (ROA) of 20.0 % which means that it generated profit of $20.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 31.54 % meaning that it created $31.54 on every $100 dollars invested by stockholders.
The company currently holds 583.93 M in liabilities with Debt to Equity (D/E) ratio of 0.05 which may suggest the company is not taking enough advantage from borrowing. Biogen Idec Inc has Current Ratio of 2.65 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen Idec Inc [BIIB] is traded on NASDAQ in USA. It is located in Cambridge, MA and employs 7,550 people.

Filter other executives

Specify Title
Indicate Tenure
Select Industry
Click to run this filter
 Run Equity Filter
Filter Other Insiders
 
Showing few of many executives

PRESIDENT Since

Darrin BeauprePharmacyclics Inc
2013
Richard RanieriBioMarin Pharmaceutical Inc
2013
John McHutchisonGilead Sciences Inc
2014
Ian SmithVertex Pharmaceuticals Incorpor
2008
Jeff AjerBioMarin Pharmaceutical Inc
2013
Betty ChangPharmacyclics Inc
2013
Robert TerifayRegeneron Pharmaceuticals Inc
2007
Rainer ErdtmannPharmacyclics Inc
2013
Charles DadswellIllumina Inc
2013
Urte GaykoPharmacyclics Inc
2013
Joseph LaRosaRegeneron Pharmaceuticals Inc
2011
Thomas DanielCelgene Corporation
2012
Gregory HemmiPharmacyclics Inc
2010
Stuart TrossAmgen Inc
2013
Peter KelloggCelgene Corporation
2014
Cynthia PattonAmgen Inc
2012
Thorsten GraefPharmacyclics Inc
2013
Paul SilvaVertex Pharmaceuticals Incorpor
2011
Michael AbermanRegeneron Pharmaceuticals Inc
2015
Fong ClowPharmacyclics Inc
2012
Scott ShearerPharmacyclics Inc
2012
SymbolBIIB
ISINUS09062X1037
CUSIP09062X103
NameBiogen Idec Inc
InstrumentUSA Stock
Analyst ConsensusBuy 17 Opinions
Risk-adjusted AdviceStrong Hold Under Valued
Average Bond RatingBBB Adequate
CurrencyUSD - US Dollar
ExchangeNASDAQ
DescriptionBiogen Inc. discovers develops manufactures and markets therapies for the treatment of neurological autoimmune and hematologic disorders in the United States and internationally. more
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Biogen Idec Inc to your portfolio

Biogen Idec Leadership

Lynn Schenk, Director
Steven Holtzman, President
Adriana Karaboutis, President
Paul Clancy, CFO, MBA
John Cox, EVP, MBA
Gregory Covino, President
Paul MBA, CFO
Robert Pangia, Director
Eric Rowinsky, Director, Ph.D
Douglas Williams, EVP
Caroline Dorsa, Director
Stuart Kingsley, EVP
MD, MBA, SVP
Richard Mulligan, Director
Stelios Papadopoulos, Chairman, Ph.D
George Scangos, CEO, Ph.D
Alexander Denner, Director
Brian Posner, Director
Stephen Sherwin, Director, Ph.D
Susan Alexander, President
Adriana MS, EVP
Kenneth Pietro, President
MD, Sandrock, SVP
Tony Kingsley, President, MBA
Nancy Leaming, Director
Alfred Sandrock, President, Ph.D
Adam Koppel, President, MBA
Spyros Artavanis-Tsakonas, President, Ph.D

Stock Performance

Shares Outstanding234.61 M
Number of Shares Shorted3.59 M